| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 121.8 | 121.6 | 136.3 |
| Other income | 4.4 | 5.1 | 8.8 |
| Total income | 126.2 | 126.6 | 145.0 |
| Profit before exceptional items & tax | 14.7 | 17.1 | 28.1 |
| Exceptional items | 0.0 | 9.1 | 0.0 |
| Profit before tax | 14.7 | 26.2 | 28.1 |
| Net profit | 9.5 | 18.6 | 21.6 |
| Operating margin | 11.6% | 20.7% | 19.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -56.00% |
|---|---|
| Net profit, quarter on quarter | -48.90% |
| Revenue, year on year | -10.60% |
| Operating profit, year on year | -46.60% |
| Operating profit, quarter on quarter | -14.20% |
BSE results filing, NSE: FERMENTA. Figures extracted from the filing.
Fermenta Biotech Ltd: key numbers
- Share price
- ₹468.15
- Market cap
- ₹1,378 Cr
- Revenue (annual)
- ₹525.4 Cr
- Net profit (annual)
- ₹71.77 Cr
- P/E (TTM)
- 22.8×Sector 50.4×
- Promoter holding
- 64.09%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fermenta Biotech Ltd
All →Fermenta Biotech Other Announcement
KMP Sumesh Gandhi sold a total of 3,900 equity shares in three separate market transactions on September 7, 8, and 9, 2026.
- Value
- ₹0.20 Cr
Fermenta Biotech Partnership
Fermenta Biotech Limited signed an exclusive licence agreement with VIT Vellore to commercialize Vitamin B12 fortification technology for fermented foods, enhancing its product portfolio.
- From
- Vellore Institute of Technology (VIT), Vellore
Fermenta Biotech Promoter Selling: ₹2.2 Cr
Director Prashant Nagre sold 44,000 shares of Fermenta Biotech Ltd via market sale. The transaction value is Rs.2.20 Crore.
- Value
- ₹2.20 Cr
- Promoter stake change
- -0.15%
Fermenta Biotech Investor Presentation: Key Takeaways
Q1FY27 revenue flat sequentially at INR 126.2 crore. Human nutrition volume grew 18% QoQ, offsetting animal nutrition weakness. EBITDA stood at INR 22.4 crore (17.7% margin).
Fermenta Biotech Earnings Call: Key Takeaways
Fermenta Biotech delivered core revenue growth of 27% YoY in FY26, driven by Vitamin D3 segments, despite headline declines from a high real-estate base in FY25.
Fermenta Biotech Q4 FY26 Results: Net Profit ₹18.6 Cr, Down 44.1% YoY
Fermenta Biotech Ltd reported revenue from operations of ₹121.6 Cr (-13.0% YoY) and net profit of ₹18.6 Cr (-44.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹18.6 Cr · -44.1% YoY